Hydroxyhexadecanoylcarnitine
Hydroxyhexadecanoylcarnitine is a long-chain acylcarnitine, a class of molecules crucial for transporting fatty acids into the mitochondria for beta-oxidation. This process is essential for generating energy, particularly during periods of fasting or high energy demand.
Biological Basis
Section titled “Biological Basis”In the body, fatty acids are activated by conversion to acyl-CoAs. Long-chain acyl-CoAs, like hexadecanoyl-CoA (palmitoyl-CoA), cannot directly cross the inner mitochondrial membrane. They require the carnitine shuttle system, involving carnitine palmitoyltransferase I (CPT-I), carnitine-acylcarnitine translocase (CACT), and carnitine palmitoyltransferase II (CPT-II), to enter the mitochondrial matrix. Hydroxyhexadecanoylcarnitine acts as an intermediate in this pathway, representing a fatty acid chain that has undergone partial beta-oxidation and is linked to carnitine. This molecule plays a vital role in the efficient breakdown of long-chain fatty acids, contributing to cellular energy production in tissues such as skeletal muscle and heart.
Clinical Relevance
Section titled “Clinical Relevance”Abnormal levels of hydroxyhexadecanoylcarnitine can indicate underlying metabolic disorders, particularly those affecting fatty acid oxidation. Elevated concentrations are often observed in conditions like very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency or carnitine palmitoyltransferase II (CPT-II) deficiency. These genetic disorders impair the body’s ability to process specific fatty acids, leading to their accumulation and potentially causing serious health issues, including cardiomyopathy, muscle weakness, hypoglycemia, and liver dysfunction. As such, hydroxyhexadecanoylcarnitine serves as an important biomarker in diagnostic testing and newborn screening programs for these conditions.
Social Importance
Section titled “Social Importance”The identification and measurement of hydroxyhexadecanoylcarnitine levels have significant social importance, primarily through their role in newborn screening. Early detection of fatty acid oxidation disorders allows for timely intervention, such as dietary modifications and carnitine supplementation, which can prevent severe clinical manifestations, reduce morbidity, and improve long-term outcomes for affected individuals. This proactive approach underscores the value of understanding specific metabolic intermediates for public health and the advancement of personalized medicine in managing rare genetic conditions.
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Genome-wide association studies (GWAS) investigating metabolites like hydroxyhexadecanoylcarnitine are subject to several methodological and statistical limitations that can influence the robustness and interpretation of findings. While efforts are made to include large sample sizes for improved statistical power, the finite nature of these cohorts can still limit the ability to detect genetic variants with small effect sizes, potentially leading to an underestimation of the full genetic architecture of a trait.[1] Furthermore, the reliance on imputation methods to infer ungenotyped variants, often based on reference panels like HapMap, introduces a degree of uncertainty, with reported imputation error rates ranging from 1.46% to 2.14% per allele, which can affect the accuracy of association signals. [2]The process of prioritizing and validating associated single nucleotide polymorphisms (SNPs) remains a fundamental challenge, as initial associations may include false positives or exhibit inflated effect sizes if not rigorously replicated in independent cohorts.[1]
Meta-analysis, a common approach to increase power, can be complicated by heterogeneity across studies, stemming from differences in sample ascertainment, genotyping platforms, or analytical pipelines. [3] Although heterogeneity is often assessed, fixed-effects models, if applied without careful consideration, might not fully account for diverse genetic effects across populations, potentially obscuring true biological relationships. Additionally, statistical strategies such as stepwise selection, used to identify significant SNPs, can sometimes lead to models that are overfit or unstable, thereby impacting the reliability and generalizability of the identified associations. [4]These statistical nuances highlight the need for cautious interpretation and extensive validation to confirm the true genetic determinants of hydroxyhexadecanoylcarnitine levels.
Ancestry and Generalizability Challenges
Section titled “Ancestry and Generalizability Challenges”A significant limitation in many genetic studies, including those relevant to metabolites like hydroxyhexadecanoylcarnitine, is the predominant focus on populations of European ancestry. Numerous large-scale GWAS and replication efforts have been conducted exclusively in individuals of self-reported European or white European descent, which severely restricts the generalizability of findings to other global populations.[5]Differences in linkage disequilibrium (LD) patterns, allele frequencies, and environmental exposures across diverse ancestral groups mean that genetic associations identified in one population may not translate directly or have the same effect size in another.[3] While some studies acknowledge this by attempting to extend findings to multi-ethnic cohorts, such as those from Singapore comprising Chinese, Malays, and Asian Indians, the initial discovery and validation phases often remain ancestry-specific, creating a cohort bias. [5]This lack of diverse representation can lead to an incomplete understanding of the genetic factors influencing hydroxyhexadecanoylcarnitine levels across humanity and may hinder the development of broadly applicable diagnostic or therapeutic strategies.
Phenotypic Nuances and Unaccounted Factors
Section titled “Phenotypic Nuances and Unaccounted Factors”The precise phenotyping and accounting for confounding variables are critical, yet complex, aspects of studying metabolites like hydroxyhexadecanoylcarnitine. Research indicates that factors such as sex can significantly influence genetic risk profiles and metabolite levels, with some genes showing distinct sex-specific effects on related lipid traits.[6]If these sex-specific differences are not adequately explored or adjusted for, the overall reported genetic associations for hydroxyhexadecanoylcarnitine could be misleading or incomplete. Furthermore, environmental factors and complex gene-environment interactions, which are often difficult to comprehensively measure and integrate into genetic models, can act as significant confounders or modifiers of genetic effects.[3] The reliance on statistical adjustments for covariates like age and sex, while necessary, may not fully capture all sources of variation or residual confounding that influence metabolite concentrations. [5]Additionally, findings from in vitro cell line studies, sometimes used to explore functional consequences of genetic variants, may not always perfectly recapitulate the complex in vivo human physiological context for hydroxyhexadecanoylcarnitine metabolism.[3] The concept of “missing heritability,” where a substantial portion of a trait’s heritability remains unexplained by identified genetic variants, also suggests that current models may not fully account for all genetic and non-genetic influences on metabolite levels. [5]
Variants
Section titled “Variants”The rs2147895 variant is located within the PYROXD2 gene, which encodes a protein believed to be involved in cellular redox processes and potentially mitochondrial function. PYROXD2 acts as an oxidoreductase, playing a role in maintaining the balance of reduction and oxidation reactions within cells. While the specific impact of rs2147895 , an intronic variant, on PYROXD2gene activity is not fully characterized, intronic single nucleotide polymorphisms (SNPs) can influence gene expression through effects on splicing, transcription, or RNA stability, thereby potentially impacting protein levels or function.[7]Such genetic variations can subtly alter metabolic pathways, including those related to fatty acid oxidation, which are crucial for energy production and directly influence acylcarnitine levels like hydroxyhexadecanoylcarnitine.[8]
Hydroxyhexadecanoylcarnitine is a type of acylcarnitine, which are molecules essential for the transport of fatty acids into the mitochondria for beta-oxidation, the process that breaks down fatty acids into energy. Genetic variations in enzymes central to fatty acid beta-oxidation significantly impact acylcarnitine levels. For instance, variants in theSCAD (short-chain acyl-Coenzyme A dehydrogenase) gene, such as rs2014355 , are strongly associated with the ratio of short-chain acylcarnitines C3 and C4. [7] Similarly, the MCAD (medium-chain acyl-Coenzyme A dehydrogenase) gene, through variants like rs11161510 , influences the ratios of various medium-chain acylcarnitines, including C0, C10, C12, C14, and C14:1. [7]These enzymes are critical steps in the degradation of fatty acids, and their genetic variability directly affects the efficiency of this process, thereby influencing the circulating levels of acylcarnitines like hydroxyhexadecanoylcarnitine.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs2147895 | PYROXD2 | hydroxyhexadecanoylcarnitine measurement arginine measurement metabolite measurement N6,N6-dimethyllysine measurement N6-methyllysine measurement |
Biological Background
Section titled “Biological Background”Metabolic Pathways and Lipid Homeostasis
Section titled “Metabolic Pathways and Lipid Homeostasis”Hydroxyhexadecanoylcarnitine is identified as an acylcarnitine, a class of biomolecules crucial for lipid metabolism. Acylcarnitines play a central role in facilitating the transport of fatty acids into the mitochondrial matrix, where they undergo beta-oxidation to produce energy. The presence and concentration of specific acylcarnitines, such as hydroxyhexadecanoylcarnitine, in human serum provide a functional readout of the body’s physiological state and its capacity for lipid processing.[7] This metabolic process is fundamental to cellular energy production and overall lipid homeostasis, interacting with the broader network of lipid and cholesterol synthesis and breakdown pathways that maintain metabolic health.
The balance of various lipid species, including cholesterol and triglycerides, is tightly regulated within the body. Disruptions in these pathways can lead to an accumulation of specific lipid intermediates or an imbalance in energy substrate utilization. The comprehensive measurement of these endogenous metabolites, through fields like metabolomics, helps to understand the complex interplay of genetic factors and environmental influences on these essential biological processes. [7]
Enzymatic Regulation of Lipid Synthesis and Transport
Section titled “Enzymatic Regulation of Lipid Synthesis and Transport”The synthesis and transport of lipids are governed by a sophisticated network of enzymes, receptors, and regulatory proteins. A key enzyme in cholesterol biosynthesis is 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which catalyzes a rate-limiting step in the mevalonate pathway. [9] The activity of HMGCR directly influences cellular cholesterol levels; a decrease in its function leads to lower intracellular cholesterol synthesis and a compensatory increase in cholesterol uptake from plasma via the LDL-receptor pathway to maintain cellular homeostasis. [3]
Beyond synthesis, enzymes like lecithin-cholesterol acyltransferase (LCAT) are vital for cholesterol esterification and reverse cholesterol transport, playing a critical role in high-density lipoprotein (HDL) metabolism. Dysfunctions or specific molecular defects inLCATcan lead to severe conditions, such as fish eye disease, underscoring its importance in systemic lipid processing[5]. [10] Furthermore, proteins like Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) are known regulators of lipid metabolism, influencing circulating triglyceride and HDL concentrations[11]. [12] Transcription factors, such as Sterol Regulatory Element-Binding Protein 2 (SREBP-2), also contribute to this intricate regulatory network by controlling genes involved in isoprenoid and adenosylcobalamin metabolism, thus orchestrating multiple facets of lipid and sterol synthesis. [13]
Genetic and Epigenetic Control of Lipid Metabolism
Section titled “Genetic and Epigenetic Control of Lipid Metabolism”Genetic variations significantly impact individual differences in lipid metabolism and susceptibility to dyslipidemia. Genome-wide association studies (GWAS) have identified numerous loci, including single nucleotide polymorphisms (SNPs), that influence lipid concentrations and contribute to the polygenic nature of dyslipidemia[2], [5]. [6] These genetic differences can affect the function and expression patterns of key genes involved in lipid pathways.
A crucial genetic regulatory mechanism is alternative splicing, where different mRNA isoforms are produced from a single gene, often leading to proteins with altered or distinct functions [14]. [15] For example, common intronic variants in the HMGCR gene, such as rs3846662 , are associated with altered alternative splicing of exon 13. This alternative splicing event produces a non-functional HMGCR variant, impacting the enzyme’s catalytic activity and ultimately influencing LDL-cholesterol levels. [3]Similarly, alternative splicing of the Apolipoprotein B (APOB) mRNA has been shown to generate novel isoforms, offering a potential mechanism to lower plasma cholesterol levels. [16] Beyond splicing, transcription factors like Hepatocyte Nuclear Factor 4 alpha (HNF4A) and Hepatocyte Nuclear Factor 1 alpha (HNF1A) play essential roles in regulating gene expression in the liver, maintaining hepatic lipid homeostasis and overall metabolic function [17], [18]. [19]
Systemic and Pathophysiological Implications
Section titled “Systemic and Pathophysiological Implications”Disruptions in lipid metabolism and the regulatory networks governing it have profound systemic and pathophysiological consequences. Imbalances in lipid profiles, often termed dyslipidemia, are a major risk factor for chronic diseases such as coronary artery disease (CAD)[2], [20]. [5] Genetic variants influencing critical enzymes or transporters, such as the hepatic cholesterol transporter ABCG8, have been identified as susceptibility factors for specific conditions like human gallstone disease.[21]
The liver plays a central role in lipid metabolism, and genetic factors influencing liver gene expression, often regulated by transcription factors like HNF4A and HNF1A, directly impact systemic lipid levels [17], [18]. [19] Furthermore, the therapeutic landscape for lipid disorders is significantly influenced by these genetic insights. HMGCR is the primary target of statin medications, and common SNPs in this gene have been shown to affect the efficacy of statin therapy, highlighting the importance of genetic background in pharmacologic response [22], [23]. [6] The modulation of alternatively spliced HMGCR mRNA levels is also being explored as a potential pharmacologic target, indicating that understanding these intricate molecular mechanisms can lead to novel therapeutic strategies. [3]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Fatty Acid Catabolism and Acylcarnitine Dynamics
Section titled “Fatty Acid Catabolism and Acylcarnitine Dynamics”Hydroxyhexadecanoylcarnitine, as an acylcarnitine, plays a central role in the energy metabolism of fatty acids, specifically facilitating their transport into mitochondria for beta-oxidation. This crucial metabolic process is initiated by enzymes such as short-chain acyl-Coenzyme A dehydrogenase (SCAD) and medium-chain acyl-Coenzyme A dehydrogenase (MCAD), which differ in their preference for fatty acid chain lengths. [7] Genetic variations, such as the intronic SNP rs2014355 in SCAD and rs11161510 in MCAD, are strongly associated with altered ratios of specific acylcarnitines, like C3/C4 for short-chain and C8/C10 for medium-chain, indicating their direct impact on the flux and efficiency of fatty acid breakdown. [7] These enzymatic steps ensure that fatty acids are properly processed to yield energy, highlighting the significance of acylcarnitine dynamics in maintaining metabolic homeostasis.
Lipid Homeostasis and Cholesterol Regulation
Section titled “Lipid Homeostasis and Cholesterol Regulation”The regulation of lipid concentrations involves a complex interplay of metabolic pathways and transcriptional control. The mevalonate pathway, critical for cholesterol biosynthesis, is tightly controlled by enzymes like 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). [9] Key transcription factors, including hepatocyte nuclear factor 4 alpha (HNF4A) and hepatocyte nuclear factor 1 alpha (HNF1A), are essential for maintaining hepatic gene expression, lipid homeostasis, and the metabolism of bile acids and plasma cholesterol. [18] Furthermore, angiopoietin-like proteins, such as ANGPTL3 and ANGPTL4, are significant regulators of overall lipid metabolism, with variations in ANGPTL4specifically linked to reduced triglycerides and increased high-density lipoprotein (HDL) levels.[11] Regulation by SREBP-2 further connects isoprenoid metabolism with adenosylcobalamin metabolism, adding another layer of complexity to lipid regulation. [13]
Gene Expression and Protein Regulatory Mechanisms
Section titled “Gene Expression and Protein Regulatory Mechanisms”Beyond transcriptional control, gene expression and protein function are finely tuned by various post-transcriptional and post-translational mechanisms. Alternative splicing of pre-mRNA is a critical regulatory process that generates protein diversity from a single gene, playing a significant role in human disease.[15]For instance, common single nucleotide polymorphisms (SNPs) inHMGCR have been shown to affect the alternative splicing of exon 13, influencing the resulting protein isoforms. [3] Similarly, antisense oligonucleotide-induced alternative splicing of APOB mRNA can generate novel protein isoforms. [16] Post-translational modifications, such as O-linked glycosylation catalyzed by enzymes like polypeptide N-acetylgalactosaminyltransferase 2 (GALNT2), also exert regulatory control over many proteins, potentially impacting those involved in HDL cholesterol and triglyceride metabolism.[24] The degradation rate of proteins, such as HMG-CoA reductase, is also subject to regulation, influenced by its oligomerization state. [25]
Systemic Metabolic Integration and Cardiovascular Disease
Section titled “Systemic Metabolic Integration and Cardiovascular Disease”The intricate network of metabolic pathways contributes to systemic lipid profiles and has broad implications for complex diseases like coronary artery disease (CAD). Genome-wide association studies have identified multiple genetic loci that collectively influence lipid concentrations and the risk of CAD, indicating a polygenic basis for dyslipidemia.[2] Dysregulation in key lipid metabolic components, such as the hepatic cholesterol transporter ABCG8, can increase susceptibility to conditions like gallstone disease.[21] Similarly, molecular defects in lecithin-cholesterol acyltransferase (LCAT) can lead to specific syndromes like fish eye disease.[26] The emerging field of metabolomics provides a comprehensive functional readout of physiological states, revealing how genetic variants impact the homeostasis of key metabolites and contribute to diverse metabolic phenotypes. [27]
The provided research does not contain specific information regarding the clinical relevance of hydroxyhexadecanoylcarnitine. Therefore, a detailed section on its clinical relevance, prognostic value, clinical applications, comorbidities, associations, or risk stratification cannot be compiled based on the given context.
References
Section titled “References”[1] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, 2007.
[2] Willer, C. J., et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 248-57.
[3] Burkhardt, R., et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arteriosclerosis, Thrombosis, and Vascular Biology, 2009.
[4] Pare, G., et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genetics, 2008.
[5] Kathiresan, S., et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56–65.
[6] Aulchenko, Y. S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, vol. 41, no. 1, 2009, pp. 47–55.
[7] Gieger, C et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.” PLoS Genet, 2008.
[8] Wallace, C et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.” Am J Hum Genet, 2008.
[9] Goldstein, J. L., and M. S. Brown. “Regulation of the mevalonate pathway.” Nature, vol. 343, no. 6257, 1990, pp. 425–30.
[10] Kuivenhoven, J. A., et al. “The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.” J Lipid Res, vol. 38, no. 2, 1997, pp. 191–205.
[11] Koishi, R., et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet, vol. 30, no. 2, 2002, pp. 151–57.
[12] Romeo, S., et al. “Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL.” Nat Genet, vol. 39, no. 4, 2007, pp. 513–16.
[13] Murphy, C., et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochem Biophys Res Commun, vol. 355, no. 2, 2007, pp. 359–64.
[14] Matlin, A. J., et al. “Understanding alternative splicing: towards a cellular code.” Nat Rev Mol Cell Biol, vol. 6, no. 5, 2005, pp. 386–98.
[15] Caceres, J. F., and A. R. Kornblihtt. “Alternative splicing: multiple control mechanisms and involvement in human disease.”Trends Genet, vol. 18, no. 4, 2002, pp. 186–93.
[16] Khoo, B., et al. “Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.” BMC Mol Biol, vol. 8, 2007, p. 3.
[17] Hayhurst, G. P., et al. “Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.” Mol Cell Biol, vol. 21, no. 4, 2001, pp. 1393–403.
[18] Odom, D. T., et al. “Control of pancreas and liver gene expression by HNF transcription factors.” Science, vol. 303, no. 5662, 2004, pp. 1378–81.
[19] Shih, D. Q., et al. “Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism.” Nat Genet, vol. 27, no. 4, 2001, pp. 375–82.
[20] Samani, N. J., et al. “Genomewide association analysis of coronary artery disease.”N Engl J Med, vol. 357, no. 5, 2007, pp. 443–53.
[21] Buch, S., et al. “A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.”Nat Genet, vol. 39, no. 8, 2007, pp. 995–99.
[22] Chasman, D. I., et al. “Pharmacogenetic study of statin therapy and cholesterol reduction.” Jama, vol. 291, no. 23, 2004, pp. 2821–27.
[23] Krauss, R. M., et al. “Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.”Circulation, vol. 117, no. 12, 2008, pp. 1537–44.
[24] Kathiresan, S., et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nature Genetics, 2008.
[25] Cheng, H. H., et al. “Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase.” The Journal of Biological Chemistry, vol. 274, no. 24, 1999, pp. 17171-17178.
[26] Francke, S., et al. “A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.”Proceedings of the National Academy of Sciences, vol. 88, no. 11, 1991, pp. 4855-4859.
[27] Nicholson, Jeremy K., et al. “Metabonomics: a platform for studying drug toxicity and gene function.” Nature Reviews Drug Discovery, vol. 1, no. 2, 2002, pp. 153-161.